PEPTIDE

Bivalirudin (Angiomax)

Direct, reversible thrombin inhibitor; binds both catalytic site and exosite I via flexible Gly-linker. Short ~25-min half-life.

BIOGATE · GREEN | POSTERIOR 56.5% | MW 2180.3 | 20AA

SEQUENCE

fPRPGGGGNGDFEEIPEEYL

Modifications: D-Phe[1]; synthetic 20-residue thrombin inhibitor

PDA-V1 chain of custody

Outer hash

826-adafb816ad968846ade21836adc8e866ae147856adfb4886ae46d87

Merkle root

2-a27cabc2b27cc4f2c27cde22d27cf752627c4702727c6032827c7962927c929

Inputs

0518187-b041816e807181ba106181a0e09181ec708181d340b1821ed0a1820

TEE attestation

9-d9928529e9929e59b99252c9c9926bf999922069a99239997991ee098992073

Living Outcome Oracle

± =60.1

² =46.3

P(success) = 56.5%

95% CI [44.5%, 68.5%]

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE A

2006 · N Engl J Med

Bivalirudin during primary PCI in acute myocardial infarction (HORIZONS-AMI)

Stone GW et al.

PMID 16540615